Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.

Expert opinion on drug discovery - 1 Jul 2016

Cazzola Mario, Calzetta Luigino, Rogliani Paola, Matera Maria Gabriella

Abstract excerpt

INTRODUCTION: Cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE)4 is an intracellular target that can be exploited to the treat chronic obstructive pulmonary disease (COPD), given that it is expressed in all inflammatory cells implicated in this inflammatory airways disease. At the present time, roflumilast is the only PDE4 inhibitor that has received regulatory approval for use in patients with COPD....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzamides
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclic Nucleotide Phosphodiesterases, Type 4

Share to Cyclopropanes

Share to Phenotype

Share to Pulmonary Disease, Chronic Obstructive

Share to Research Design

Source

Identifiers

PMID: 27169612
DOI: 10.1080/17460441.2016.1184642

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.PMID 27169612Read ↗

New and existing pharmacotherapeutic options for persistent asthma and COPD.Semantic proximity Read ↗

Efficacy of roflumilast in the COPD frequent exacerbator phenotype.Semantic proximity Read ↗

Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?Semantic proximity Read ↗

Positioning new pharmacotherapies for COPD.Semantic proximity Read ↗

Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic BronchitisSemantic proximity Read ↗

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.Semantic proximity Read ↗

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.Semantic proximity Read ↗

The role of Transient Receptor Potential (TRP) channels in the pathogenesis of COPDSemantic proximity Read ↗

Phenotyping patients with chronic cough: Evaluating the ability to predict the response to anti-inflammatory therapy.Semantic proximity Read ↗

"Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease": a consensus document.Semantic proximity Read ↗

A Novel Quinoline With Airway Relaxant Effects and Anti-Inflammatory PropertiesSemantic proximity Read ↗

Procalcitonin-Guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations (PRECISION): Study Protocol for a Prospective Randomized Controlled Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.